Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic disease triggered by commonly used potent inhalation anaesthetics and/or succinylcholine. The in vitro muscle contracture test (IVCT) is the standard test to establish an individual's risk of susceptibility to MH. 1 The European MH Group has developed a standardized protocol for the IVCT and has initiated and fostered international collaborative molecular genetic studies to investigate the molecular basis of MH. Data from these studies demonstrate that MH displays a high level of locus heterogeneity. Thus, it is not feasible to diagnose MH susceptibility, and, more speci®cally, to exclude MH risk, on the basis of a simple genetic test alone. However, it is of utmost importance to avoid false MH-negative (MHN) diagnoses because of the potential risk of MH during general anaesthesia for these patients and their offspring. These general obstacles notwithstanding, there may be speci®c situations where genetic data provide additional diagnostic information or contribute information independent of IVCT. It is the purpose of this document to outline recommended procedures for the potential diagnostic use of such genetic ®ndings depending on the different clinical situations that may arise.
Referrals
The usual route of entry for individuals into MH investigations follows a suspected MH crisis and referral of the patient to an MH Investigation Unit, where diagnostic procedures and genetic counselling should be performed according to Figure 1 .
IVCT
An IVCT is performed on the patient or, if the patient is too young or has not survived the anaesthetic event, his or her parents. If MH susceptibility status is con®rmed by IVCT, then there is a clinical responsibility to offer the IVCT to the relatives of the index case, assuming autosomal dominant inheritance and starting with ®rst-degree relatives.
Genetic investigations

Mutation analysis
At this stage, molecular genetic testing for causative mutations in the ryanodine receptor gene (RYR1) of the index case could lead to quicker results for the rest of the kinship. An up-to-date list of mutations that have been shown to directly alter RYRI caffeine or halothane sensitivity is shown in Table 1 .
Genetic analysis should be performed in, or only after consultation with an MH Investigation Unit. Once a causative mutation has been detected in the proband or index patient, it can be used to test relatives who have not yet been tested by the IVCT. Mutation carriers should consequently be regarded as susceptible to MH. However, family members who do not carry the mutation observed in the pedigree should still undergo IVCT investigation. The reason for such caution is the observation in several pedigrees investigated by members of the European MH Group of discordance between genetic and IVCT results, implicating a second MH susceptibility gene segregating in the kinship. 2 3 
Segregation analysis
Once the MH status of the extended pedigree (e.g. 10 informative meioses) has been determined by the IVCT, it may be possible to undertake genetic segregation analysis with markers close to known MH susceptibility loci. An upto-date list of recommended markers and details of genetic modelling compiled by the European Malignant Hyperthermia Group, Genetics Section, is available on the internet (http://www.emhg.org).
Rarely, a single pedigree may be suf®ciently large to establish linkage to a candidate locus with a high probability (lod score >3.0). In such a situation the question arises as to whether or not haplotype analysis can be used to assign MH status. Under these circumstances, individuals carrying the high-risk haplotype should be regarded as susceptible to MH even without con®rmation by a positive IVCT. The converse is not true, that is, identi®cation of the low-risk haplotype does not equate with MHN status and such individuals should have IVCT determination of their MH status.
In families where linkage to a candidate gene, RYR1 or another locus, is suggested but not ®rmly established (i.e. lod score <3.0) haplotype analysis for predictive testing is not appropriate due to the high level of locus heterogeneity in MH. In such families, however, it is desirable to search for unknown mutations in the suggested candidate gene for research purposes.
Failure to reach a lod score of +3.0 in a single family due to the occurrence of a single individual in whom there is recombination between the haplotype and IVCT-deter- 
